Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

AI Briefing

• – Neurocrine Biosciences initiates Phase 1 clinical study for NBIP-'2118, a CRF2R agonist for weight loss with lean mass preservation.
• – The study aims to evaluate the safety and tolerability of the new compound.
• – NBIP-'2118 targets a novel mechanism for weight loss.